Related Experiment Video
Updated: Nov 1, 2025
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
Published on: November 17, 2018
Traceable metallic antigen release for enhanced cancer immunotherapy
Fangfang Lv1, Yan Jin2, Xiaochen Feng2
1College of Pharmaceutical Science, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Chemical Biology Key Laboratory of Hebei Province, Institute of Life Science and Green Development, Hebei University, Baoding, 071002 China.
This study introduces a novel traceable nanovaccine for melanoma treatment. The nanovaccine uses gold nanoclusters and upconversion nanoparticles (UCNPs) to improve antigen delivery and monitoring, enhancing therapeutic effects.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Immunotherapy
Background:
- Tumor vaccines show promise in immunotherapy but face challenges with rapid antigen clearance by the reticuloendothelium system, limiting therapeutic efficacy.
- Monitoring the distribution and fate of antigens within the body remains difficult, hindering vaccine development and optimization.
Purpose of the Study:
- To develop a traceable nanovaccine for melanoma treatment that overcomes antigen clearance issues and allows for fate monitoring.
- To synthesize and evaluate a nanovaccine platform combining gold nanocluster-labeled antigens with upconversion nanoparticles (UCNPs).
Main Methods:
- Synthesized a nanovaccine using gold nanocluster-labeled ovalbumin antigens conjugated to upconversion nanoparticles (UCNPs) via a pH-sensitive Schiff base bond.
- Evaluated the nanovaccine's biocompatibility, pH-sensitive antigen release, and therapeutic effects in melanoma models.
Main Results:
- The developed UCNPs-conjugated metallic antigen nanovaccine demonstrated excellent biocompatibility.
- The nanovaccine exhibited pH-sensitive release of antigens, enabling monitoring of their release dynamics.
- The nanovaccine showed significant therapeutic effects in melanoma treatment.
Conclusions:
- The novel traceable nanovaccine platform effectively addresses antigen clearance limitations in tumor immunotherapy.
- This approach allows for real-time monitoring of antigen distribution and release, paving the way for improved melanoma treatment strategies.
